April D Thames1, Natalie Arbid2, Philip Sayegh3. 1. Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, 740 Westwood Plaza C8-226, Los Angeles, CA 90095, United States. Electronic address: athames@mednet.ucla.edu. 2. Greater Los Angeles VA Healthcare System, 11301 Wilshire Blvd Building 226, Los Angeles, CA 90024, United States. 3. Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, 740 Westwood Plaza C8-226, Los Angeles, CA 90095, United States.
Abstract
OBJECTIVE: With the recent debates over marijuana legalization and increases in use, it is critical to examine its role in cognition. While many studies generally support the adverse acute effects of cannabis on neurocognition, the non-acute effects remain less clear. The current study used a cross-sectional design to examine relationships between recent and past cannabis use on neurocognitive functioning in a non-clinical adult sample. METHOD: One hundred and fifty-eight participants were recruited through fliers distributed around local college campuses and the community. All participants completed the Brief Drug Use History Form, the Structured Clinical Interview for DSM-IV Disorders, and neurocognitive assessment, and underwent urine toxicology screening. Participants consisted of recent users (n=68), past users (n=41), and non-users (n=49). RESULTS: Recent users demonstrated significantly (p<.05) worse performance than non-users across cognitive domains of attention/working memory (M=42.4, SD=16.1 vs. M=50.5, SD=10.2), information processing speed (M=44.3, SD=7.3 vs. M=52.1, SD=11.0), and executive functioning (M=43.6, SD=13.4 vs. M=48.6, SD=7.2). There were no statistically significant differences between recent users and past users on neurocognitive performance. Frequency of cannabis use in the last 4 weeks was negatively associated with global neurocognitive performance and all individual cognitive domains. Similarly, amount of daily cannabis use was negatively associated with global neurocognitive performance and individual cognitive domains. CONCLUSIONS: Our results support the widespread adverse effects of cannabis use on neurocognitive functioning. Although some of these adverse effects appear to attenuate with abstinence, past users' neurocognitive functioning was consistently lower than non-users.
OBJECTIVE: With the recent debates over marijuana legalization and increases in use, it is critical to examine its role in cognition. While many studies generally support the adverse acute effects of cannabis on neurocognition, the non-acute effects remain less clear. The current study used a cross-sectional design to examine relationships between recent and past cannabis use on neurocognitive functioning in a non-clinical adult sample. METHOD: One hundred and fifty-eight participants were recruited through fliers distributed around local college campuses and the community. All participants completed the Brief Drug Use History Form, the Structured Clinical Interview for DSM-IV Disorders, and neurocognitive assessment, and underwent urine toxicology screening. Participants consisted of recent users (n=68), past users (n=41), and non-users (n=49). RESULTS: Recent users demonstrated significantly (p<.05) worse performance than non-users across cognitive domains of attention/working memory (M=42.4, SD=16.1 vs. M=50.5, SD=10.2), information processing speed (M=44.3, SD=7.3 vs. M=52.1, SD=11.0), and executive functioning (M=43.6, SD=13.4 vs. M=48.6, SD=7.2). There were no statistically significant differences between recent users and past users on neurocognitive performance. Frequency of cannabis use in the last 4 weeks was negatively associated with global neurocognitive performance and all individual cognitive domains. Similarly, amount of daily cannabis use was negatively associated with global neurocognitive performance and individual cognitive domains. CONCLUSIONS: Our results support the widespread adverse effects of cannabis use on neurocognitive functioning. Although some of these adverse effects appear to attenuate with abstinence, past users' neurocognitive functioning was consistently lower than non-users.
Authors: Jennifer J Manly; Diane M Jacobs; Pegah Touradji; Scott A Small; Yaakov Stern Journal: J Int Neuropsychol Soc Date: 2002-03 Impact factor: 2.892
Authors: Scott D Lane; Don R Cherek; Oleg V Tcheremissine; Lori M Lieving; Cythia J Pietras Journal: Neuropsychopharmacology Date: 2005-04 Impact factor: 7.853
Authors: Krista M Lisdahl; Rachel Thayer; Lindsay M Squeglia; Tim M McQueeny; Susan F Tapert Journal: Psychiatry Res Date: 2012-11-13 Impact factor: 3.222
Authors: Olivier J Barthelemy; Mark A Richardson; Timothy C Heeren; Clara A Chen; Jane M Liebschutz; Leah S Forman; Howard J Cabral; Deborah A Frank; Ruth Rose-Jacobs Journal: J Stud Alcohol Drugs Date: 2019-01 Impact factor: 2.582
Authors: April D Thames; Taylor P Kuhn; Timothy J Williamson; Jacob D Jones; Zanjbeel Mahmood; Andrea Hammond Journal: Drug Alcohol Depend Date: 2016-11-14 Impact factor: 4.492
Authors: James Gilleen; Marcello Tesse; Tjasa Velikonja; Mark Weiser; Michael Davidson; Abraham Reichenberg Journal: Schizophr Res Date: 2020-07-04 Impact factor: 4.939
Authors: Amanda R Bolbecker; Deborah Apthorp; Ashley Schnakenberg Martin; Behdad Tahayori; Leah Moravec; Karen L Gomez; Brian F O'Donnell; Sharlene D Newman; William P Hetrick Journal: Drug Alcohol Depend Date: 2018-06-21 Impact factor: 4.492
Authors: Diana H Fishbein; Scott P Novak; Ty A Ridenour; Vanessa Thornburg; Jane Hammond; Jaki Brown Journal: J Stud Alcohol Drugs Date: 2016-05 Impact factor: 2.582